Back to News
Market Impact: 0.1
ORIC Pharmaceuticals, Inc. Announces Phase 1b Enozertinib Data and Plans for Phase 3 Redwood-1 Trial in 1H 2027
Source: Nasdaq
Healthcare & Biotech
ORIC Pharmaceuticals presented an update on its enozertinib (ORIC-114) program at ESMO Congress 2026 on October 23, 2026. The available article text says the update covered Phase 1b trial data in patients with locally advanced or metastatic non-small cell lung cancer, but provides no results or numerical findings.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ORIC0.30
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
- Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall